Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02091141 · ClinicalTrials.gov registry record · Phase 2
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 673
- Enrollment target
NCT02091141: Completed Phase 2 study, sponsored by Genentech.
NCT02091141 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 673 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (406% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02091141, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 673 participants
- Enrollment target
Study Summary
This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.
Primary Outcome
The Objective Response Rate (ORR) is defined as the percentage of patients whose best response on or before the first occurrence of disease progression is a complete response (CR) or partial response (PR). Tumor responses were assessed by investigators using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for all arms.
Interventions
- DRUG Trastuzumab
- DRUG Vemurafenib
- DRUG Pertuzumab
- DRUG Cobimetinib
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 673 participants |
| Start Date | 2014-04-14 |
| Est. Completion | 2023-05-24 |
| Phase | Phase 2 |
What the finished NCT02091141 record still lists
NCT02091141 is an interventional study that assigns participants to a tested intervention. The registered 673 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (406% higher).
The record links to 0 conditions, and to 5 interventions - of which Trastuzumab is the first listed.
NCT02091141 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02091141 about?
NCT02091141 is a clinical study titled "My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors". This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.
What is the current status of trial NCT02091141?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 673 participants. The study started on 2014-04-14. Estimated completion is 2023-05-24.
What interventions are being tested in trial NCT02091141?
The interventions under investigation include: Trastuzumab (DRUG), Vemurafenib (DRUG), Pertuzumab (DRUG), Cobimetinib (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT02091141?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02091141's enrollment target sits among peer trials
673 48th of 2000 higher than 1,953 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06335381 · 674 participants · NA
MOMs Chat and Care Study
- NCT06757634 · 674 participants · Phase 3
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- NCT05452031 · 672 participants · NA
A Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers
- NCT05493254 · 672 participants · NA
Enhancing Smoking Cessation Via Telehealth Options in Primary Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI